Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.

Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH

Journal of medical economics24 May 2012Cited by 15 (Europe PMC)

PMID22533526DOI10.3111/13696998.2012.688903PepBankPUB-22533526

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyOther
In adults with type 2 diabetes in a US claims database, total 6-month costs were similar for liraglutide ($7346) and exenatide ($6688).
In plain wordsIn US adults with type 2 diabetes, total costs over 6 months were similar for liraglutide and exenatide.
Peptide
Liraglutide
Outcome
No significant changeTotal 6-month follow-up costs
Study
n: not reported in source
Comparator
Exenatide BID
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Mean total 6-month cost
7346 $
liraglutide
Mean total 6-month cost
6688 $
exenatide
Source sentences
Summary
Matched exenatide and liraglutide cohorts (n=1347 pairs) had similar average total 6-month follow-up costs ($6688 vs $7346).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort analysis comprising adult patients with T2DM who initiated exenatide or liraglutide between 1/1/2010 and 6/30/2010 and had 6 months pre-index and post-index continuous eligibility.
Report a problemFND-2253352601
02HumanObservational studyOther
In adults with type 2 diabetes in a US claims database, mean pharmacy costs were higher with liraglutide ($3272) than with exenatide ($2925).
In plain wordsIn US adults with type 2 diabetes, medicine costs were higher with liraglutide than with exenatide.
Peptide
Liraglutide
Outcome
IncreaseMean pharmacy costs
Study
n: not reported in source
Comparator
Exenatide BID
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Mean pharmacy cost
3272 $
liraglutide
Mean pharmacy cost
2925 $
exenatide
Source sentences
Summary
However, exenatide patients had significantly lower mean pharmacy costs ($2925 vs $3272, p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort analysis comprising adult patients with T2DM who initiated exenatide or liraglutide between 1/1/2010 and 6/30/2010 and had 6 months pre-index and post-index continuous eligibility.
Report a problemFND-2253352602
03HumanObservational studyOther
In adults with type 2 diabetes in a US claims database, average total costs were higher with liraglutide 1.8 mg ($8031) than with 1.2 mg ($6536).
In plain wordsIn US adults with type 2 diabetes, total costs were higher for people on liraglutide 1.8 mg than on 1.2 mg.
Peptide
Liraglutide
Outcome
IncreaseTotal costs, liraglutide 1.8 mg versus 1.2 mg
Study
n: not reported in source
Comparator
Liraglutide 1.2 mg
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
1.8 mgAs given in this study (human).
Measurements
Mean total cost
8031 $
liraglutide 1.8 mg
Mean total cost
6536 $
liraglutide 1.2 mg
Source sentences
Summary
Among liraglutide patients, patients receiving the 1.8 mg dose had significantly higher average total costs compared to those receiving the 1.2 mg dose ($8031 vs $6536, p=0.026)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort analysis comprising adult patients with T2DM who initiated exenatide or liraglutide between 1/1/2010 and 6/30/2010 and had 6 months pre-index and post-index continuous eligibility.
Report a problemFND-2253352603
04HumanObservational studyOther
In adults with type 2 diabetes in a US claims database, mean pharmacy costs were higher with liraglutide 1.8 mg ($3935) than with 1.2 mg ($3146).
In plain wordsIn US adults with type 2 diabetes, medicine costs were higher for people on liraglutide 1.8 mg than on 1.2 mg.
Peptide
Liraglutide
Outcome
IncreasePharmacy costs, liraglutide 1.8 mg versus 1.2 mg
Study
n: not reported in source
Comparator
Liraglutide 1.2 mg
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
1.8 mgAs given in this study (human).
Measurements
Mean pharmacy cost
3935 $
liraglutide 1.8 mg
Mean pharmacy cost
3146 $
liraglutide 1.2 mg
Source sentences
Summary
with higher mean pharmacy costs in the 1.8 mg cohort ($3935 vs $3146, p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort analysis comprising adult patients with T2DM who initiated exenatide or liraglutide between 1/1/2010 and 6/30/2010 and had 6 months pre-index and post-index continuous eligibility.
Report a problemFND-2253352604
05HumanObservational studyOther
In adults with type 2 diabetes in a US claims database, inpatient costs did not differ between liraglutide and exenatide.
In plain wordsIn US adults with type 2 diabetes, hospital stay costs were not different between liraglutide and exenatide.
Peptide
Liraglutide
Outcome
No significant changeInpatient costs
Study
n: not reported in source
Comparator
Exenatide BID
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
There were no significant differences in inpatient or outpatient costs or medication adherence between groups (mean PDC: exenatide 56% vs liraglutide 57%, p=0.088).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort analysis comprising adult patients with T2DM who initiated exenatide or liraglutide between 1/1/2010 and 6/30/2010 and had 6 months pre-index and post-index continuous eligibility.
Report a problemFND-2253352605
06HumanObservational studyOther
In adults with type 2 diabetes in a US claims database, outpatient costs did not differ between liraglutide and exenatide.
In plain wordsIn US adults with type 2 diabetes, outpatient costs were not different between liraglutide and exenatide.
Peptide
Liraglutide
Outcome
No significant changeOutpatient costs
Study
n: not reported in source
Comparator
Exenatide BID
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
There were no significant differences in inpatient or outpatient costs or medication adherence between groups (mean PDC: exenatide 56% vs liraglutide 57%, p=0.088).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort analysis comprising adult patients with T2DM who initiated exenatide or liraglutide between 1/1/2010 and 6/30/2010 and had 6 months pre-index and post-index continuous eligibility.
Report a problemFND-2253352606
07HumanObservational studyOther
In adults with type 2 diabetes in a US claims database, medication adherence was similar for liraglutide (mean PDC 57%) and exenatide (56%).
In plain wordsIn US adults with type 2 diabetes, people took liraglutide and exenatide as prescribed about equally often.
Peptide
Liraglutide
Outcome
No significant changeMedication adherence (proportion of days covered)
Study
n: not reported in source
Comparator
Exenatide BID
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Mean PDC
57%
liraglutide
Mean PDC
56%
exenatide
Source sentences
Summary
There were no significant differences in inpatient or outpatient costs or medication adherence between groups (mean PDC: exenatide 56% vs liraglutide 57%, p=0.088).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort analysis comprising adult patients with T2DM who initiated exenatide or liraglutide between 1/1/2010 and 6/30/2010 and had 6 months pre-index and post-index continuous eligibility.
Report a problemFND-2253352607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms